145 related articles for article (PubMed ID: 38758967)
1. Radiation enhancement using focussed ultrasound-stimulated microbubbles for breast cancer: A Phase 1 clinical trial.
Moore-Palhares D; Dasgupta A; Saifuddin M; Anzola Pena ML; Prasla S; Ho L; Lu L; Kung J; McNabb E; Sannachi L; Vesprini D; Chen H; Karam I; Soliman H; Szumacher E; Chow E; Gandhi S; Trudeau M; Curpen B; Stanisz GJ; Kolios M; Czarnota GJ
PLoS Med; 2024 May; 21(5):e1004408. PubMed ID: 38758967
[TBL] [Abstract][Full Text] [Related]
2. Radiation enhancement using focussed ultrasound-stimulated microbubbles for head and neck cancer: A phase 1 clinical trial.
Moore-Palhares D; Saifuddin M; Dasgupta A; Anzola Pena ML; Prasla S; Ho L; Lu L; Kung J; Karam I; Poon I; Bayley A; McNabb E; Stanisz G; Kolios M; Czarnota GJ
Radiother Oncol; 2024 Jun; 198():110380. PubMed ID: 38879128
[TBL] [Abstract][Full Text] [Related]
3. Novel MRI-guided focussed ultrasound stimulated microbubble radiation enhancement treatment for breast cancer.
Dasgupta A; Saifuddin M; McNabb E; Ho L; Lu L; Vesprini D; Karam I; Soliman H; Chow E; Gandhi S; Trudeau M; Tran W; Curpen B; Stanisz G; Sahgal A; Kolios M; Czarnota GJ
Sci Rep; 2023 Aug; 13(1):13566. PubMed ID: 37604988
[TBL] [Abstract][Full Text] [Related]
4. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial-a study protocol.
Civil YA; Oei AL; Duvivier KM; Bijker N; Meijnen P; Donkers L; Verheijen S; van Kesteren Z; Palacios MA; Schijf LJ; Barbé E; Konings IRHM; -van der Houven van Oordt CWM; Westhoff PG; Meijer HJM; Diepenhorst GMP; Thijssen V; Mouliere F; Slotman BJ; van der Velde S; van den Bongard HJGD
BMC Cancer; 2023 May; 23(1):419. PubMed ID: 37161377
[TBL] [Abstract][Full Text] [Related]
7. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Vicini FA; Cecchini RS; White JR; Arthur DW; Julian TB; Rabinovitch RA; Kuske RR; Ganz PA; Parda DS; Scheier MF; Winter KA; Paik S; Kuerer HM; Vallow LA; Pierce LJ; Mamounas EP; McCormick B; Costantino JP; Bear HD; Germain I; Gustafson G; Grossheim L; Petersen IA; Hudes RS; Curran WJ; Bryant JL; Wolmark N
Lancet; 2019 Dec; 394(10215):2155-2164. PubMed ID: 31813636
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
9. Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation.
Vasmel JE; Charaghvandi RK; Houweling AC; Philippens MEP; van Asselen B; Vreuls CPH; van Diest PJ; van Leeuwen AMG; van Gorp J; Witkamp AJ; Koelemij R; Doeksen A; Sier MF; van Dalen T; van der Wall E; van Dam I; Veldhuis WB; Kirby AM; Verkooijen HM; van den Bongard HJGD
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):821-829. PubMed ID: 31812720
[TBL] [Abstract][Full Text] [Related]
10. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol.
Charaghvandi RK; van Asselen B; Philippens ME; Verkooijen HM; van Gils CH; van Diest PJ; Pijnappel RM; Hobbelink MG; Witkamp AJ; van Dalen T; van der Wall E; van Heijst TC; Koelemij R; van Vulpen M; van den Bongard HJ
BMC Cancer; 2017 Mar; 17(1):181. PubMed ID: 28274211
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-mediated microbubble enhancement of radiation therapy studied using three-dimensional high-frequency power Doppler ultrasound.
Kwok SJ; El Kaffas A; Lai P; Al Mahrouki A; Lee J; Iradji S; Tran WT; Giles A; Czarnota GJ
Ultrasound Med Biol; 2013 Nov; 39(11):1983-90. PubMed ID: 23993051
[TBL] [Abstract][Full Text] [Related]
13. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt A; Haviland JS; Wheatley DA; Sydenham MA; Alhasso A; Bloomfield DJ; Chan C; Churn M; Cleator S; Coles CE; Goodman A; Harnett A; Hopwood P; Kirby AM; Kirwan CC; Morris C; Nabi Z; Sawyer E; Somaiah N; Stones L; Syndikus I; Bliss JM; Yarnold JR;
Lancet; 2020 May; 395(10237):1613-1626. PubMed ID: 32580883
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.
Sahgal A; Myrehaug SD; Siva S; Masucci GL; Maralani PJ; Brundage M; Butler J; Chow E; Fehlings MG; Foote M; Gabos Z; Greenspoon J; Kerba M; Lee Y; Liu M; Liu SK; Thibault I; Wong RK; Hum M; Ding K; Parulekar WR;
Lancet Oncol; 2021 Jul; 22(7):1023-1033. PubMed ID: 34126044
[TBL] [Abstract][Full Text] [Related]
17. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
Whelan TJ; Julian JA; Berrang TS; Kim DH; Germain I; Nichol AM; Akra M; Lavertu S; Germain F; Fyles A; Trotter T; Perera FE; Balkwill S; Chafe S; McGowan T; Muanza T; Beckham WA; Chua BH; Gu CS; Levine MN; Olivotto IA;
Lancet; 2019 Dec; 394(10215):2165-2172. PubMed ID: 31813635
[TBL] [Abstract][Full Text] [Related]
18. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
; Bentzen SM; Agrawal RK; Aird EG; Barrett JM; Barrett-Lee PJ; Bliss JM; Brown J; Dewar JA; Dobbs HJ; Haviland JS; Hoskin PJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Morgan DA; Owen JR; Simmons S; Sumo G; Sydenham MA; Venables K; Yarnold JR
Lancet Oncol; 2008 Apr; 9(4):331-41. PubMed ID: 18356109
[TBL] [Abstract][Full Text] [Related]
19. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
20. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM;
Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
